Fluoxetine tenth anniversary update: the progress continues

Richelson, 1993, Treatment of acute depression, Psychiatr Clin North Am, 16, 461, 10.1016/S0193-953X(18)30160-6 Thase, 1996, Recent developments in the pharmacotherapy of mood disorders, J Consult Clin Psychol, 64, 646, 10.1037/0022-006X.64.4.646 Katon, 1992, Adequacy and duration of antidepressant treatment in primary care, Med Care, 30, 67, 10.1097/00005650-199201000-00007 Wells, 1994, Use of minor tranquilizers and antidepressant medications by depressed outpatients: Results from the medical outcomes study, Am J Psychiatry, 151, 694, 10.1176/ajp.151.5.694 Preskorn, 1994, Antidepressant drug selection: Criteria and options, J Clin Psychiatry, 55, 6 Wong, 1995, Minireview: Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publication, Life Sci, 57, 411, 10.1016/0024-3205(95)00209-O Guze, 1994, New antidepressants and the treatment of depression, J Fam Pract, 38, 49 1992, Psychopharmacologic drugs, 1, 32 Beasley, 1990, Fluoxetine in tricyclic refractory major depressive disorder, J Affect Disord, 20, 193, 10.1016/0165-0327(90)90144-W Lader, 1988, Fluoxetine efficacy vs comparative drugs: An overview, Br J Psychiatry, 153, 51, 10.1192/S0007125000297298 Montgomery, 1988, The prophylactic efficacy of fluoxetine in unipolar depression, Br J Psychiatry, 153, 69, 10.1192/S0007125000297328 Reimherr, 1984, Characteristics of responders to fluoxetine, Psychopharmacol Bull, 20, 70 Liebowitz, 1988, Antidepressant specificity in atypical depression, Arch Gen Psychiatry, 45, 129, 10.1001/archpsyc.1988.01800260037004 Donoghue, 1995, A comparison of prescribing patterns of selective serotonin reuptake inhibitors in the treatment of depression in primary care in the United Kingdom, J Serotonin Res, 1, 47 Stokes, 1993, Fluoxetine: A five-year review, Clin Ther, 15, 216 Asberg, 1976, 5-HIAA in cerebrospinal fluid—a biochemical suicide predictor?, Arch Gen Psychiatry, 33, 1193, 10.1001/archpsyc.1976.01770100055005 Leonard, 1995, SSRI differentiation: Pharmacology and pharmacokinetics, Hum Psychopharmacol, 10, S149, 10.1002/hup.470100903 171995, Prozac® (fluoxetine hydrochloride) Cohen, 1996, Clinical implications of antidepressant pharmacokinetics and pharmacogenetics, Ann Pharmacother, 3, 1471, 10.1177/106002809603001216 Menys, 1996, Platelet 5-hydroxytryptamine is decreased in a preliminary group of depressed patients receiving the 5-hydroxytryptamine re-uptake inhibiting drug fluoxetine, Clin Sci, 91, 87, 10.1042/cs0910087 Baumann, 1996, Pharmacokinetic-pharmaco-dynamic relationship of the selective serotonin reuptake inhibitors, Clin Pharmacokinet, 31, 444, 10.2165/00003088-199631060-00004 Catterson, 1996, Pharmacokinetics of selective serotonin reuptake inhibitors: Clinical relevance, Pharmacol Toxicol, 78, 203, 10.1111/j.1600-0773.1996.tb00206.x Ereshefsky, 1995, Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6, Clin Pharmacokinet, 29, 10, 10.2165/00003088-199500291-00004 Preskorn, 1994, Inhibition of hepatic P-450 isoenzymes by serotonin selective reuptake inhibitors: In vitro and in vivo findings and their implications for patient care, Psychopharmacol Bull, 30, 251 Rasmussen, 1994, Fluvoxamine is a potent inhibitor of cytochrome P4501A2, Psychopharmacology (Berl), 114, B9 Nemeroff, 1996, Newer antidepressants and the cytochrome P450 system, Am J Psychiatry, 153, 311, 10.1176/ajp.153.3.311 Riesenman, 1995, Antidepressant drug interactions and the cytochrome P450 system: A critical appraisal, Pharmacotherapy, 15, 84S, 10.1002/j.1875-9114.1995.tb02909.x Krishnan, 1996, Drug interactions, Prim Psychiatry, 23 Krishnan, 1996, Drug interactions, Prim Psychiatry, 35 Ketter, 1995, The emerging role of cytochrome P450 3A in psychopharmacology, J Clin Psychopharmacol, 15, 387, 10.1097/00004714-199512000-00002 von Moltke, 1995, Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology, Clin Pharmacokinet, 29, 33, 10.2165/00003088-199500291-00007 Crewe, 1992, The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes, Br J Clin Pharmacol, 34, 262, 10.1111/j.1365-2125.1992.tb04134.x Otton, 1993, Inhibition by fluoxetine of cytochrome P450 2D6 activity, Clin Pharmacol Ther, 53, 401, 10.1038/clpt.1993.43 Glue, 1996, Psychiatry, psychopharmacology and P-450s, Hum Psychopharmacol, 11, 97, 10.1002/(SICI)1099-1077(199603)11:2<97::AID-HUP759>3.0.CO;2-7 Taylor, 1996, Cytochromes and psychotropic drug interactions, Br J Psychiatry, 168, 529, 10.1192/bjp.168.5.529 Park, 1995, The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity, Pharmacol Ther, 68, 385, 10.1016/0163-7258(95)02013-6 Bergstrom, 1992, Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction, Clin Pharmacol Ther, 51, 239, 10.1038/clpt.1992.18 von Moltke, 1996, Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: Relation to pharmacokinetic interactions in vivo, J Clin Psychopharmacol, 16, 104, 10.1097/00004714-199604000-00002 Ereshefsky, 1996, Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system, J Clin Psychiatry, 57, 17 Marinac, 1995, Dextromethorphan polymorphic hepatic oxidation in healthy black American adult subjects, Ther Drug Monit, 17, 120, 10.1097/00007691-199504000-00003 DeVane, 1994, Pharmacogenetics and drug metabolism of newer antidepressant agents, J Clin Psychiatry, 55, 38 Bertilsson, 1995, Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19, Clin Pharmacokinet, 29, 192, 10.2165/00003088-199529030-00005 Katz, 1997, Can the effects of antidepressants be observed in the first two weeks of treatment?, Neuropsychopharmacology, 17, 110 Katz, 1987, The timing, specificity and clinical prediction of tricyclic drug effects in depression, Psychol Med, 17, 297, 10.1017/S0033291700024831 Holman, 1994, Onset of action in depressed patients treated with fluoxetine or placebo, Neuropsychopharmacology, 10, 162S Bel, 1992, Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nucle: An in vivo microdialysis study, Eur J Pharmacol, 229, 101, 10.1016/0014-2999(92)90292-C de Montigny, 1978, Tricyclic antidepressants: Long-term treatment increases responsivity of rat forebrain neurons to serotonin, Science, 202, 1303, 10.1126/science.725608 Chaput, 1988, Acute and long-term effects of antidepressant serotonin (5-HT) reuptake blockers on the efficacy of 5-HT neurotransmission: Electrophysiological studies in the rat central nervous system, Adv Biol Psychiatr, 17, 1, 10.1159/000416212 Welner, 1989, Autoradiographic quantification of serotonin1A receptors in rat brain following antidepressant drug treatment, Synapse, 4, 347, 10.1002/syn.890040410 Moret, 1990, Serotonin autoreceptor subsensitivity and antidepressant activity, Eur J Pharmacol, 180, 351, 10.1016/0014-2999(90)90320-6 Nielsen, 1993, A comparison of fluoxetine and imipramine in the treatment of outpatients with major depressive disorder, Acta Psychiatr Scand, 87, 269, 10.1111/j.1600-0447.1993.tb03370.x Workman, 1993, Atypical antidepressants versus imipramine in the treatment of major depression: A meta-analysis, J Clin Psychiatry, 54, 5 Bowden, 1993, Fluoxetine and desipramine in major depressive disorder, J Clin Psychopharmacol, 13, 305, 10.1097/00004714-199310000-00002 Remick, 1993, Comparison of fluoxetine and desipramine in depressed outpatients, Curr Ther Res, 53, 457, 10.1016/S0011-393X(05)80653-8 Fabre, 1991, Comparative efficacy and safety of nortriptyline and fluoxetine in the treatment of major depression: A clinical study, J Clin Psychiatry, 52, 62 Beasley, 1993, Fluoxetine versus amitriptyline in the treatment of major depression: A multicenter trial, Int Clin Psychopharmacol, 8, 143, 10.1097/00004850-199300830-00002 Judd, 1993, A multicentre double-blind trial of fluoxetine versus amitriptyline in the treatment of depressive illness, Aust New Zealand J Psychiatry, 27, 49, 10.3109/00048679309072123 Feighner, 1985, Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder, J Clin Psychiatry, 46, 20 Robertson, 1994, A double-blind, controlled comparison of fluoxetine and lofepramine in major depressive illness, J Psychopharmacol, 8, 98, 10.1177/026988119400800205 Souetre, 1996, Quality of life in depressed patients: Comparison of fluoxetine and major tricyclic antidepressants, Int Clin Psychopharmacol, 11, 45, 10.1097/00004850-199603000-00006 De Wilde, 1993, A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients, Acta Psychiatr Scand, 87, 141, 10.1111/j.1600-0447.1993.tb03345.x Tignol, 1993, A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression, J Clin Psychopharmacol, 13, 18S, 10.1097/00004714-199312002-00003 Gagiano, 1993, A double-blind comparison of paroxetine and fluoxetine in patients with major depression, Br J Clin Res, 4, 145 Aguglia, 1993, Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression, Int Clin Psychopharmacol, 8, 197, 10.1097/00004850-199300830-00010 van Moffaert, 1995, A controlled comparison of sertraline and fluoxetine in acute and continuation treatment of major depression, Hum Psychopharmacol, 10, 393, 10.1002/hup.470100505 Bennie, 1995, A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression, J Clin Psychiatry, 56, 229 Rapaport, 1996, A comparison of fluvoxamine and fluoxetine in the treatment of major depression, J Clin Psychopharmacol, 16, 373, 10.1097/00004714-199610000-00005 Patris, 1996, Citalopram versus fluoxetine: A double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice, Int Clin Psychopharmacol, 11, 129 Gregor, 1994, Selective serotonin reuptake inhibitor dose titration in the naturalistic setting, Clin Ther, 16, 306 Anderson, 1995, Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: A meta-analysis, BMJ, 310, 1433, 10.1136/bmj.310.6992.1433 Montgomery, 1994, Selective serotonin reuptake inhibitors: Meta-analysis of discontinuation rates, Int Clin Psychopharmacol, 9, 47, 10.1097/00004850-199400910-00008 Montgomery, 1995, Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: A meta-analysis, Int Clin Psychopharmacol, 9, 33, 10.1097/00004850-199501004-00005 Danjou, 1994, A randomized, double-blind comparison of venlafaxine and fluoxetine in inpatients with major depression and melancholia, Neuropsychopharmacology, 10, 222S Clerc, 1994, A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia, Int Clin Psychopharmacol, 9, 138, 10.1097/00004850-199409000-00001 Dierick, 1996, A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients, Prog Neuropsychopharmacol Biol Psychiatry, 20, 57, 10.1016/0278-5846(95)00292-8 Tylee, 1996, A comparison of venlafaxine 37.5 mg twice a day with fluoxetine 20 mg once a day in depressed patients treated in general practice, Psychopharmacol Bull, 32, 528 Ellingrod, 1994, Venlafaxine: A heterocyclic antidepressant, Am J Hosp Pharm, 51, 3033 Mendels, 1995, A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients, J Clin Psychiatry, 56, 30 Rioux, 1996, A double-blind comparison of nefazodone and fluoxetine in depressed patients, Psychopharmacol Bull, 32, 505 Williams, 1993, A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disorders, Int Clin Psychopharmacol, 7, 155, 10.1097/00004850-199300730-00006 Lonnqvist, 1994, Antidepressant efficacy and quality of life in depression: A double-blind study with moclobemide and fluoxetine, Acta Psychiatr Scand, 89, 363, 10.1111/j.1600-0447.1994.tb01530.x Geerts, 1994, Moclobemide versus fluoxetine for major depressive episodes, Clin Neuropharmacol, 17, S50, 10.1097/00002826-199417001-00007 de Kock, 1994, A double-blind, multicentre study with moclobemide and fluoxetine in treatment of major depressive episode, Neuropsychopharmacology, 10, 61S Gattaz, 1994, Moclobemide vs fluoxetine in the treatment of major depression, Neuropsychopharmacology, 10, 62S Reynaert, 1995, Moclobemide versus fluoxetine for a major depressive episode, Psychopharmacology, 118, 183, 10.1007/BF02245838 Lonnqvist, 1995, Moclobemide and fluoxetine in the prevention of relapses following acute treatment of depression, Acta Psychiatr Scand, 91, 189, 10.1111/j.1600-0447.1995.tb09765.x Donoghue, 1996, A comparison of prescribing patterns of selective serotonin reuptake inhibitors in the treatment of depression in primary care in the United Kingdom, J Serotonin Res, 1, 47 Montgomery, 1989, The efficacy of fluoxetine as an antidepressant in the short and long term, Int Clin Psychopharmacol, 4, 113 Pande, 1993, Severity of depression and response to fluoxetine, Int Clin Psychopharmacol, 8, 243, 10.1097/00004850-199300840-00006 Levine, 1987, A comparative trial of a new antidepressant, fluoxetine, Br J Psychiatry, 150, 653, 10.1192/bjp.150.5.653 Martensson, 1989, Fluoxetine treatment of depression. Clinical effects, drug concentrations, and monoamine metabolites and N-terminally extended substance P in cerebrospinal fluid, Acta Psychiatr Scand, 79, 586, 10.1111/j.1600-0447.1989.tb10307.x Hale, 1991, The utility of serotonin reuptake inhibitors in endogenous and severe depression, 15 Evans, 1992, Depression in the elderly physically ill: An open study of treatment with the 5-HT reuptake inhibitor fluoxetine, J Clin Exp Gerontol, 14, 297 Roose, 1994, Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia, Am J Psychiatry, 151, 1735, 10.1176/ajp.151.12.1735 Dunlop, 1990, Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression, Psychopharmacol Bull, 26, 173 Orengo, 1996, The use and tolerability of fluoxetine in geropsychiatric inpatients, J Clin Psychiatry, 57, 12 Wells, 1989, The functioning and well-being of depressed patients: Results from the Medical Outcomes Study, JAMA, 262, 914, 10.1001/jama.262.7.914 Ravindran, 1994, Therapeutic efficacy of specific serotonin reuptake inhibitors (SSRIs) in dysthymia, Can J Psychiatry, 39, 21, 10.1177/070674379403900106 Hellerstein, 1993, A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia, Am J Psychiatry, 150, 1169, 10.1176/ajp.150.8.1169 Rosenthal, 1992, A preliminary study of serotonergic antidepressants in treatment of dysthymia, Prog Neuropsychopharmacol Biol Psychiatry, 16, 933, 10.1016/0278-5846(92)90111-Q Hellerstein, 1996, Follow-up assessment of medication-treated dysthymia, Prog Neuropsychopharmacol Biol Psychiatry, 20, 427, 10.1016/0278-5846(96)00007-3 Hellerstein, 1994, Long-term treatment of double depression: A preliminary study with serotonergic antidepressants, Prog Neuropsychopharmacol Biol Psychiatry, 18, 139, 10.1016/0278-5846(94)90030-2 Duarte, 1996, Moclobemide versus fluoxetine for double depression: A randomized double-blind study, J Psychiatr Res, 30, 453, 10.1016/S0022-3956(96)00030-1 Johnson, 1992, Service utilization and social morbidity associated with depressive symptoms in the community, JAMA, 267, 1478, 10.1001/jama.267.11.1478 Broadhead, 1990, Depression, disability days, and days lost from work in a prospective epidemiologic survey, JAMA, 264, 2524, 10.1001/jama.264.19.2524 Hamilton, 1988, Distinguishing between anxiety and depressive disorders, 143 Liebowitz, 1993, Depression with anxiety and atypical depression, J Clin Psychiatry, 54, 10 Schatzberg, 1995, Fluoxetine in the treatment of comorbid anxiety and depression, J Clin Psychiatry Monogr, 3, 2 1994 Feighner, 1985, A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder, J Clin Psychiatry, 45, 369 Tollefson, 1993, Comorbid anxious signs and symptoms in major depression: Impact on functional work capacity and comparative treatment outcomes, Int Clin Psychopharmacol, 8, 281, 10.1097/00004850-199300840-00013 Beasley, 1991, High dose fluoxetine: Efficacy and activating-sedating effects in agitated and retarded depression, J Clin Psychopharmacol, 11, 166 Tollefson, 1994, Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features, J Clin Psychiatry, 55, 50 Moskowitz, 1988, The effects on performance of two antidepressants, alone and in combination with diazepam, Prog Neuropsychopharmacol Biol Psychiatry, 12, 783, 10.1016/0278-5846(88)90023-1 Filteau, 1995, SSRIs in anxious-agitated depression: A post-hoc analysis of 279 patients, Int Clin Psychopharmacol, 10, 51, 10.1097/00004850-199503000-00007 Sheehan, 1996, The role of SSRIs in panic disorder, J Clin Psychiatry, 57, 51 den Boer, 1995, Serotonergic compounds in panic disorder, obsessive-compulsive disorder and anxious depression: A concise review, Hum Psychopharmacol, 10, S173, 10.1002/hup.470100906 Gorman, 1987, An open trial of fluoxetine in the treatment of panic attacks, J Clin Psychopharmacol, 7, 329, 10.1097/00004714-198710000-00007 Schneier, 1990, Fluoxetine in panic disorder, J Clin Psychopharmacol, 10, 119, 10.1097/00004714-199004000-00007 Louie, 1993, Use of low-dose fluoxetine in major depression and panic disorder, J Clin Psychiatry, 54, 435 Emmanuel, 1996, The efficacy of once a week fluoxetine dosing in the treatment of panic disorder, Psychopharmacol Bull, 32, 438 Satterlee, 1995, The effects of fluoxetine on symptoms of insomnia in depressed patients, Psychopharmacol Bull, 31, 227 Tollefson, 1993, Analysis of the Hamilton Depression Rating Scale factors from a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression, Int Clin Psychopharmacol, 8, 253, 10.1097/00004850-199300840-00008 Schatzberg, 1996, SSRI treatment controversies: The elderly, J Clin Psychiatry Intercom, 1 1992, Diagnosis and treatment of depression in late life, JAMA, 268, 1018, 10.1001/jama.268.8.1018 Tollefson, 1995, A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression, Int Psychogeriatr, 7, 89, 10.1017/S1041610295001888 Koran, 1995, Predicting response to fluoxetine in geriatric patients with major depression, J Clin Psychopharmacol, 15, 421, 10.1097/00004714-199512000-00006 Small, 1995, Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression, Int Psychogeriatr, 7, 41, 10.1017/S1041610295002341 McWilliam, 1994, A naturalistic study into the use of fluoxetine in elderly depressive patients, Neuropsychopharmacology, 10, 101S Heiligenstein, 1995, Acute effects of fluoxetine versus placebo on functional health and well-being in late-life depression, Int Psychogeriatr, 7, 125, 10.1017/S1041610295002407 Schone, 1993, A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression, J Clin Psychopharmacol, 13, 34S Geretsegger, 1994, Paroxetine in the elderly depressed patient: Randomized comparison with fluoxetine of efficacy, cognitive and behavioral effects, Int Clin Psychopharmacol, 9, 25, 10.1097/00004850-199400910-00004 La Pia, 1992, Evaluation of the efficacy, tolerability, and therapeutic profile of fluoxetine versus mianserin in the treatment of depressive disorders in the elderly, Curr Ther Res, 52, 847, 10.1016/S0011-393X(05)80057-8 La Pia, 1992, Double blind controlled study to evaluate the effectiveness and tolerability of fluoxetine versus mianserin in the treatment of depressive disorders among the elderly and their effects on cognitive-behavioral parameters, New Trends Exp Clin Psychiatry, 8, 139 Nobler, 1996, Fluoxetine treatment of dysthymia in the elderly, J Clin Psychiatry, 57, 254 Fairweather, 1993, A double blind comparison of the effects of fluoxetine and amitriptyline on cognitive function in elderly depressed patients, Hum Psychopharmacol, 8, 41, 10.1002/hup.470080108 Alderman, 1993, A retrospective review of fluoxetine use in an acute care geriatric hospital, Aust J Hosp Pharm, 23, 116 Mesters, 1993, Assessment of quality of life in the treatment of major depressive disorder with fluoxetine, 20 mg, in ambulatory patients aged over 60 years, Int Clin Psychopharmacol, 8, 337, 10.1097/00004850-199300840-00024 Gregoire, 1994, Validation of the Quality of Life in Depression scale in a population of adult depressive patients aged 60 and above, Q Life Res, 3, 13, 10.1007/BF00647844 Devanand, 1997, Fluoxetine discontinuation in elderly dysthymic patients, Am J Geriatr Psychiatry, 5, 83, 10.1097/00019442-199700510-00011 Salzman, 1993, Pharmacologic treatment of depression in the elderly, J Clin Psychiatry, 54, 23 Harris, 1995, Fluoxetine, Drugs Aging, 6, 64, 10.2165/00002512-199506010-00006 Brymer, 1992, Fluoxetine in elderly patients: Is there cause for concern?, J Am Geriatr Soc, 40, 912, 10.1111/j.1532-5415.1992.tb01987.x Sharma, 1996, Antidepressant-induced hyponatraemia in the aged. Avoidance and management strategies, Drugs Aging, 8, 430, 10.2165/00002512-199608060-00004 Greden, 1993, Antidepressant maintenance medications: When to discontinue and how to stop, J Clin Psychiatry, 54, 39 Blomgren SL, Fava M, Ascroft RC, et al. Risk of adverse events and depressive symptom breakthrough following brief interruptive selective serotonin reuptake inhibitor therapy in a randomized clinical trial. Submitted for publication. Tollefson, 1994, Is baseline agitation a relative contraindication for a selective serotonin reuptake inhibitor? A comparative trial of fluoxetine versus imipramine, J Clin Psychopharmacol, 14, 385, 10.1097/00004714-199412000-00003 Spiker, 1985, The pharmacological treatment of delusional depression, Am J Psychiatry, 142, 430, 10.1176/ajp.142.4.430 Narayan, 1995, Fluoxetine-induced delusions in psychotic depression, J Clin Psychiatry, 56, 7 Rothschild, 1993, Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression, J Clin Psychiatry, 54, 338 Schatzberg, 1992, Psychotic (delusional) major depression: Should it be included as a distinct syndrome in DSM-IV?, Am J Psychiatry, 149, 733, 10.1176/ajp.149.6.733 McElroy, 1993, Body dysmorphic disorder: Does it have a psychotic subtype?, J Clin Psychiatry, 54, 389 Meltzer, 1994, An overview of the mechanism of action of clozapine, J Clin Psychiatry, 55, 47 Flint, 1996, The effect of sequential antidepressant treatment on geriatric depression, J Affect Disord, 36, 95, 10.1016/0165-0327(95)00063-1 Amsterdam, 1994, Fluoxetine efficacy in treatment resistant depression, Prog Neuropsychopharmacol Biol Psychiatry, 18, 243, 10.1016/0278-5846(94)90057-4 Simon, 1996, Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants, JAMA, 275, 1897, 10.1001/jama.275.24.1897 Weilburg, 1989, Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: A preliminary report, J Clin Psychiatry, 50, 447 Zajecka, 1995, The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: A retrospective analysis, J Clin Psychiatry, 56, 338 Horgan, 1993, Combined fluoxetine and desipramine in resistant depression, Aust New Zealand J Psychiatry, 27, 166 Phillips, 1994, The assessment and treatment of refractory depression, J Clin Psychiatry, 55, 20 Nesse, 1996, Management of depression in patients with coexisting medical illness, Am Fam Phys, 53, 2125 Glassman, 1979, Clinical characteristics of imipramine-induced orthostatic hypotension, Lancet, 1, 468, 10.1016/S0140-6736(79)90824-9 Glassman, 1978, Tricyclic blood levels and clinical outcomes: A review of the art, 917 Stoudemire, 1995, Expanding psychopharmacologic treatment options for the depressed medical patient, Psychosomatics, 36, S19, 10.1016/S0033-3182(95)71700-5 Shuster, 1992, Pros and cons of fluoxetine for the depressed cancer patient, Oncology, 6, 45 Koriech, 1995, Fluoxetine treatment comprimises the antiemetic efficacy of ondansetron in cancer patients, Clin Oncol, 7, 371, 10.1016/S0936-6555(05)80007-X Razavi, 1996, The effect of fluoxetine on anxiety and depression symptoms in cancer patients, Acta Psychiatr Scand, 94, 205, 10.1111/j.1600-0447.1996.tb09850.x Hynes, 1982, The effect of fluoxetine on morphine analgesia, respiratory depression, and lethality, Drug Dev Res, 2, 33, 10.1002/ddr.430020105 Humphries, 1990, Fluoxetine and the bleeding time, Arch Pathol Lab Med, 114, 727 Stamenkovic, 1996, Poststroke depression and fluoxetine, Am J Psychiatry, 153, 446, 10.1176/ajp.153.3.446b Targ, 1994, Structured group therapy and fluoxetine to treat depression in HIV-positive persons, Psychosomatics, 35, 132, 10.1016/S0033-3182(94)71786-2 Rabkin, 1994, Effects of fluoxetine on mood and immune status in depressed patients with HIV illness, J Clin Psychiatry, 55, 92 Singh, 1994, Fluoxetine treatment of major depression in patients with AIDS, Neuropsychopharmacology, 10, 94S Ghaziuddin, 1994, Fluoxetine and blood glucose control in adolescents with major depression and insulin-dependent diabetes mellitus, J Child Adolesc Psychopharmacol, 4, 87, 10.1089/cap.1994.4.87 Lonnqvist, 1994, Moclobemide and fluoxetine in atypical depression: A double-blind trial, J Affect Disord, 32, 169, 10.1016/0165-0327(94)90015-9 Stratta, 1991, A double-blind, parallel study comparing fluoxetine with imipramine in the treatment of atypical depression, Int Clin Psychopharmacol, 6, 193, 10.1097/00004850-199100630-00007 Shrand, 1995, Psychopharmacology in mood and anxiety disorders, Contemp Pediatr, 12, 21 Hazell, 1995, Efficacy of tricyclic drugs in treating child and adolescent depression: A meta-analysis, BMJ, 310, 897, 10.1136/bmj.310.6984.897 Ghaziuddin, 1995, Fluoxetine in tricyclic refractory depression in adolescents, Depression, 2, 287, 10.1002/depr.3050020602 DeVane, 1996, Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: A review of published experience, J Clin Psychiatry, 57, 55 Colle, 1994, Extended open-label fluoxetine treatment of adolescents with major depression, J Child Adolesc Psychopharmacol, 4, 225, 10.1089/cap.1994.4.225 Simeon, 1990, Adolescent depression: A placebo-controlled fluoxetine treatment study and follow-up, Prog Neuropsychopharmacol Biol Psychiatry, ???, 791, 10.1016/0278-5846(90)90050-Q Boulos, 1992, An open naturalistic trial of fluoxetine in adolescents and young adults with treatment-resistant major depression, J Child Adolesc Psychopharmacol, 2, 103, 10.1089/cap.1992.2.103 Jain, 1992, Fluoxetine in children and adolescents with disorders: A chart review of efficacy and adverse effects, J Child Adolesc Psychopharmacol, 2, 259, 10.1089/cap.1992.2.259 Garland, 1995, Subgroups of adolescent depression, J Am Acad Child Adolesc Psychiatry, 34, 831, 10.1097/00004583-199507000-00001 Dummit, 1996, Fluoxetine treatment of children with selective mutism: An open trial, J Am Acad Child Adolesc Psychiatry, 35, 615, 10.1097/00004583-199605000-00016 Pfeffer, 1989, Psychopathology and plasma cortisol responses to dexamethasone in prepubertal psychiatric inpatients, Biol Psychiatry, 26, 677, 10.1016/0006-3223(89)90102-9 Piacentini, 1992, Psychopharmacologic treatment of child and adolescent obsessive compulsive disorder, Pediatr Psychopharmacol, 15, 87 Rasmussen, 1992, The epidemiology and clinical features of OCD, Psychiatr Clin North Am, 15, 743, 10.1016/S0193-953X(18)30205-3 Riddle, 1992, Double-blind crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder, J Am Acad Child Adolesc Psychiatry, 31, 1062, 10.1097/00004583-199211000-00011 Riddle, 1990, Fluoxetine treatment of children and adolescents with Tourette's and obsessive compulsive disorder: Preliminary clinical experience, J Am Acad Child Adolesc Psychiatry, 29, 45, 10.1097/00004583-199001000-00008 Geller, 1995, Similarities in response to fluoxetine in the treatment of children and adolescents with obsessive-compulsive disorder, J Am Acad Child Adolesc Psychiatry, 34, 36, 10.1097/00004583-199501000-00011 Bouvard, 1993, Fluoxetine in obsessive compulsive disorder in adolescents, Int Clin Psychopharmacol, 8, 307, 10.1097/00004850-199300840-00016 Liebowitz, 1990, Fluoxetine for adolescents with obsessive-compulsive disorder, Am J Psychiatry, 147, 370, 10.1176/ajp.147.3.370b Bussing, 1993, Methamphetamine and fluoxetine treatment of a child with attention-deficit hyperactivity disorder and obsessive-compulsive disorder, J Child Adolesc Psychopharmacol, 3, 53, 10.1089/cap.1993.3.53 Alessi, 1991, Buspirone augmentation of fluoxetine in a depressed child with obsessive-compulsive disorder, Am J Psychiatry, 148, 1605, 10.1176/ajp.148.11.1605 Graae, 1992, Response of obsessive-compulsive disorder and trichotillomania to serotonin reuptake blockers, Am J Psychiatry, 149, 149, 10.1176/ajp.149.1.149-a Cox, 1993, Clomipramine, fluoxetine, and behavior therapy in the treatment of obsessive-compulsive disorder: A meta-analysis, J Behav Ther Exp Psychiatry, 24, 149, 10.1016/0005-7916(93)90043-V Birmaher, 1994, Fluoxetine for childhood anxiety disorders, J Am Acad Child Adolesc Psychiatry, 33, 993, 10.1097/00004583-199409000-00009 Black, 1994, Treatment of elective mutism with fluoxetine: A double-blind, placebo-controlled study, J Am Acad Child Adolesc Psychiatry, 33, 1000, 10.1097/00004583-199409000-00010 Manassis, 1994, Fluoxetine in anxiety disorders, J Am Acad Child Adolesc Psychiatry, 33, 761, 10.1097/00004583-199406000-00025 Rosenbaum, 1992, Comorbidity of parental anxiety disorders as risk for childhood-onset anxiety in inhibited children, Am J Psychiatry, 149, 475, 10.1176/ajp.149.4.475 Biederman, 1993, A 3-year follow-up of children with and without behavioral inhibition, J Am Acad Child Adolesc Psychiatry, 32, 814, 10.1097/00004583-199307000-00016 Goldstein, 1995, Long-term fluoxetine treatment of bulimia nervosa, Br J Psychiatry, 166, 660, 10.1192/bjp.166.5.660 Advokat, 1995, Pharmacotherapy of the eating disorders: A commentary, Neurosci Biobehav Rev, 19, 59, 10.1016/0149-7634(94)00044-2 Levine, 1992, Fluoxetine in the treatment of bulimia nervosa, Arch Gen Psychiatry, 49, 139, 10.1001/archpsyc.1992.01820020059008 Wheadon, 1991, Fluoxetine in the long-term treatment of bulimia nervosa, Clin Res, 39, 769A Wood, 1993, Pharmacotherapy of bulimia nervosa—experience with fluoxetine, Int Clin Psychopharmacol, 8, 295, 10.1097/00004850-199300840-00014 Goldbloom, 1993, Pharmacotherapy of bulimia nervosa with fluoxetine: Assessment of clinically significant attitudinal change, Am J Psychiatry, 150, 770, 10.1176/ajp.150.5.770 Bretz, 1993, Effects of fluoxetine on the oral environment of bulimics, Oral Microbiol Immunol, 8, 62, 10.1111/j.1399-302X.1993.tb00545.x Gwirtsman, 1990, Fluoxetine treatment of anorexia nervosa: An open clinical trial, J Clin Psychiatry, 51, 378 Kaye, 1991, An open trial of fluoxetine in patients with anorexia nervosa, J Clin Psychiatry, 52, 464 Brambilla, 1995, Combined cognitive-behavioral, psychopharmacological and nutritional therapy in eating disorders. 1. Anorexia nervosa—restricted type, Neuropsychobiology, 32, 59, 10.1159/000119213 Brambilla, 1995, Combined cognitive-behavioral, psychopharmacological and nutritional therapy in eating disorders. 2. Anorexia nervosa—binge-eating/purging type, Neuropsychobiology, 32, 64, 10.1159/000119214 Pryor, 1995, Obsessive-compulsive disorder, trichotillomania, and anorexia nervosa: A case report, Int J Eating Disord, 18, 375, 10.1002/1098-108X(199512)18:4<375::AID-EAT2260180412>3.0.CO;2-S 1996, National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity, JAMA, 276, 1907, 10.1001/jama.276.23.1907 Goldstein, 1995, Efficacy and safety of long-term fluoxetine treatment of obesity—maximizing success, Obes Res, 3, 481S, 10.1002/j.1550-8528.1995.tb00216.x Levine, 1989, Use of fluoxetine, a selective serotonin uptake inhibitor, in the treatment of obesity: A dose-response study, Int J Obes, 13, 635 Goldstein, 1994, Fluoxetine: A randomized clinical trial in the treatment of obesity, Int J Obes, 18, 129 Wise, 1992, Clinical studies with fluoxetine in obesity, Am J Clin Nutr, 55, 181S, 10.1093/ajcn/55.1.181s Sayler, 1994, Evaluating success of weight loss programs, with an application to fluoxetine weight reduction clinical trial data, Int J Obes, 18, 742 Goldstein, 1991, Fluoxetine treatment of obese patients with noninsulin dependent diabetes mellitus, Clin Res, 39, 767A Connolly, 1995, A study of fluoxetine in obese elderly patients with type 2 diabetes, Diabetic Med, 12, 416, 10.1111/j.1464-5491.1995.tb00505.x Regier, 1993, One-month prevalence of mental disorders in the United States and sociodemographic characteristics: The Epidemiologic Catchment Area Study, Acta Psychiatr Scand, 88, 35, 10.1111/j.1600-0447.1993.tb03411.x Robins, 1984, Lifetime prevalence of specific psychiatric disorders in three sites, Arch Gen Psychiatry, 41, 949, 10.1001/archpsyc.1984.01790210031005 Goodman, 1992, Pharmacotherapy of obsessive-compulsive disorder, J Clin Psychiatry, 35, 29 Perse, 1988, Obsessive-compulsive disorder: A treatment review, J Clin Psychiatry, 49, 48 Piccinelli, 1995, Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review, Br J Psychiatry, 166, 424, 10.1192/bjp.166.4.424 Greist, 1995, Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis, Arch Gen Psychiatry, 52, 53, 10.1001/archpsyc.1995.03950130053006 Goodman, 1989, The Yale-Brown Obsessive Compulsive Scale. Part 1. Development, use and reliability, Arch Gen Psychiatry, 46, 1006, 10.1001/archpsyc.1989.01810110048007 Wheadon, 1993, A fixed dose comparison of 20, 40, or 60 mg paroxetine to placebo in the treatment of obsessive-compulsive disorder., Poster presented at the American College of Neuropharmacology Meeting López-Ibor, 1996, Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder, Eur Neuropsychopharmacol, 6, 111, 10.1016/0924-977X(95)00071-V Pigott, 1990, Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder, Arch Gen Psychiatry, 47, 926, 10.1001/archpsyc.1990.01810220042005 Saiz Ruiz, 1992, Double-blind comparison of fluoxetine and clomipramine in obsessive-compulsive disorder, Eur Neuropsychopharmacol, 2, 204, 10.1016/0924-977X(92)90064-F Pato, 1991, 13 Pato, 1988, Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder, Am J Psychiatry, 145, 1521, 10.1176/ajp.145.12.1521 Ravizza, 1996, Drug treatment of obsessive-compulsive disorder (OCD): Long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs), Psychopharmacol Bull, 32, 167 Laird, 1996, Issues in the monotherapy and polypharmacotherapy of obsessive-compulsive disorder, Psychopharmacol Bull, 32, 569 Iancu, 1996, Serotonergic drugs in trichotillamania: Treatment results in 12 patients, J Nerv Ment Dis, 184, 641, 10.1097/00005053-199610000-00011 Christenson, 1996, The characterization and treatment of trichotillomania, J Clin Psychiatry, 57, 42 Steiner, 1995, Fluoxetine in the treatment of premenstrual dysphoria, NEJM, 332, 1529, 10.1056/NEJM199506083322301 Wood, 1992, Treatment of premenstrual syndrome with fluoxetine: A double-blind, placebo-controlled, crossover study, Obstet Gynecol, 80, 339 Menkes, 1993, Fluoxetine's spectrum of action in premenstrual syndrome, Int Clin Psychopharmacol, 8, 95, 10.1097/00004850-199300820-00003 Pearlstein, 1994, Long-term fluoxetine treatment of late luteal phase dysphoric disorder, J Clin Psychiatry, 55, 332 Nierenberg, 1995, Early nonresponse to fluoxetine as a predictor of poor 8-week outcome, Am J Psychiatry, 152, 1500, 10.1176/ajp.152.10.1500 Quitkin, 1987, Use of pattern analysis to identify true drug response: A replication, Arch Gen Psychiatry, 44, 259, 10.1001/archpsyc.1987.01800150071009 Pope, 1988, Possible synergism between fluoxetine and lithium in refractory depression, Am J Psychiatry, 145, 1292, 10.1176/ajp.145.10.1292 Ontiveros, 1991, Refractory depression: The addition of lithium to fluoxetine or desipramine, Acta Psychiatr Scand, 83, 188, 10.1111/j.1600-0447.1991.tb05522.x Fava, 1994, Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: A double-blind, placebo-controlled study, Am J Psychiatry, 151, 1372, 10.1176/ajp.151.9.1372 Katona, 1995, Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine, Br J Psychiatry, 166, 80, 10.1192/bjp.166.1.80 Hawley, 1994, Tolerability of combined treatment with lithium and fluoxetine: 14 Cases treated under open conditions, Int Clin Psychopharmacol, 9, 31, 10.1097/00004850-199400910-00005 Bauer, 1996, Adverse events and tolerability of the combination of fluoxetine/lithium compared with fluoxetine, J Clin Psychopharmacol, 16, 130, 10.1097/00004714-199604000-00005 Breuel, 1995, Pharmacokinetic interactions between lithium and fluoxetine after single and repeated fluoxetine administration in young healthy volunteers, Int J Clin Pharmacol Ther, 33, 415 Muly, 1993, Serotonin syndrome produced by a combination of fluoxetine and lithium, Am J Psychiatry, 150, 1565, 10.1176/ajp.150.10.1565 Flint, 1994, A prospective study of lithium augmentation in antidepressant-resistant geriatric depression, J Clin Psychopharmacol, 14, 353, 10.1097/00004714-199410000-00012 Pérez, 1997, Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment, Lancet, 349, 1594, 10.1016/S0140-6736(96)08007-5 Blier, 1994, Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression, J Clin Psychopharmacol, 15, 217, 10.1097/00004714-199506000-00011 Moreno, 1996, Pindolol augmentation in treatment-resistant depressed patients, Psychopharmacol Bull, 32, 492 Berman, 1997, Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: A double-blind, placebo-controlled trial, Am J Psychiatry, 154, 37, 10.1176/ajp.154.1.37 El-Yazigi, 1995, Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone, J Clin Pharmacol, 35, 17, 10.1002/j.1552-4604.1995.tb04740.x Nelson, 1991, A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression, Arch Gen Psychiatry, 48, 303, 10.1001/archpsyc.1991.01810280019002 Tiffon, 1994, Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients, J Clin Psychiatry, 55, 66 Jacobsen, 1991, Possible augmentation of antidepressant response by buspirone, J Clin Psychiatry, 52, 217 Joffe, 1993, An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression, J Clin Psychiatry, 54, 269 Markovitz, 1990, Buspirone augmentation of fluoxetine in obsessive-compulsive disorder, Am J Psychiatry, 147, 798, 10.1176/ajp.147.6.798 Jenike, 1991, Buspirone augmentation of fluoxetine in patients with obsessive-compulsive disorder, J Clin Psychiatry, 52, 13 Grady, 1993, Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder, Am J Psychiatry, 150, 819, 10.1176/ajp.150.5.819 Leonard, 1994, Clonazepam as an augmenting agent in the treatment of childhood-onset obsessive-compulsive disorder, J Am Acad Child Adolesc Psychiatry, 33, 792, 10.1097/00004583-199407000-00003 Smith, 1996, Clonazepam augmentation of fluoxetine in the treatment of outpatients with major depression: A double-blind, placebo-controlled, multicenter study, Psychopharmacol Bull, 32, 519 Stoll, 1996, Methylphenidate augmentation of serotonin selective reuptake inhibitors: A case series, J Clin Psychiatry, 57, 72 Barak, 1996, Thyroxine augmentation of fluoxetine treatment for resistant depression in the elderly: An open trial, Hum Psychopharmacol, 11, 463, 10.1002/(SICI)1099-1077(199611)11:6<463::AID-HUP816>3.0.CO;2-H Stokes, 1995, The potential role of excessive cortisol induced by HPA hyperfunction in the pathogenesis of depression, Eur Neuropsychopharmacol, 77, 10.1016/0924-977X(95)00039-R Dinan, 1997, Dexamethasone augmentation in treatment-resistant depression, Acta Psychiatr Scand, 95, 58, 10.1111/j.1600-0447.1997.tb00374.x Stokes, 1996, A primary care perspective on management of acute and long-term depression, J Clin Psychiatry, 54, 74 Montgomery, 1996, Efficacy in long-term treatment of depression, J Clin Psychiatry, 57, 24 Tollefson, 1993, Adverse drug reactions/interactions in maintenance therapy, J Clin Psychiatry, 54, 48 Montgomery, 1994, Long-term treatment of depression, Br J Psychiatry, 165, 31, 10.1192/S0007125000293264 Fava, 1995, Relapse in patients on long-term fluoxetine treatment: Response to increased fluoxetine dose, J Clin Psychiatry, 56, 52 Frenkel, 1990, Efficacy of long-term fluoxetine treatment of obsessive-compulsive disorder, Mt Sinai J Med, 57, 348 Levine, 1989, Long-term fluoxetine treatment of a large number of obsessive-compulsive patients, J Clin Psychopharmacol, 9, 281, 10.1097/00004714-198908000-00008 Fava, 1995, Withdrawal syndromes after paroxetine and sertraline discontinuation, J Clin Psychopharmacol, 15, 374, 10.1097/00004714-199510000-00012 Coupland, 1996, Serotonin reuptake inhibitor withdrawal, J Clin Psychopharmacol, 16, 356, 10.1097/00004714-199610000-00003 1997, Prozac®, 935 Beasley, 1993, Fluoxetine: Activating and sedating effects, Int Clin Psychopharmacol, 8, 271, 10.1097/00004850-199300840-00011 Amsterdam, 1994, Efficacy of alprazolam in reducing fluoxetine-induced jitteriness in patients with major depression, J Clin Psychiatry, 55, 394 Shen, 1995, Female sexual side effects associated with selective serotonin reuptake inhibitors: A descriptive clinical study of 33 patients, Int J Psychiatry Med, 25, 239, 10.2190/N6C0-DWX2-G4EA-7688 Hsu, 1995, Male sexual side effects associated with antidepressants: A descriptive clinical study of 32 patients, Int J Psychiatry Med, 25, 191, 10.2190/1DHU-Y7L7-9GKG-V7WV Patterson, 1993, Fluoxetine-induced sexual dysfunction, J Clin Psychiatry, 54, 2 Zajecka, 1991, The role of serotonin in sexual dysfunction: Fluoxetine-associated orgasm dysfunction, J Clin Psychiatry, 52, 66 Modell, 1997, Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline, Clin Pharmacol Ther, 61, 476, 10.1016/S0009-9236(97)90198-3 Jacobsen, 1992, Fluoxetine-induced sexual dysfunction and an open trial of yohimbine, J Clin Psychiatry, 53, 119 Benazzi, 1994, Fluoxetine-induced sexual dysfunction: A dose-dependent effect?, Pharmacopsychiatry, 27, 246, 10.1055/s-2007-1014313 Lane, 1997, A critical review of selective serotonin reuptake inhibitor-related sexual dysfunction; incidence, possible aetiology and implications for management, J Psychopharmacol, 11, 72, 10.1177/026988119701100117 Balogh, 1992, Treatment of fluoxetine-induced anorgasmia with amantadine, J Clin Psychiatry, 53, 212 Walker, 1993, Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion, J Clin Psychiatry, 54, 459 Cohen, 1992, Fluoxetine-induced yawning and anorgasmia reversed by cyproheptadine treatment, J Clin Psychiatry, 53, 174 Aizenberg, 1995, Cyproheptadine treatment of sexual dysfunction induced by serotonin reuptake inhibitors, Clin Neuropharmacol, 18, 320, 10.1097/00002826-199508000-00003 Shrivastava, 1995, Amantadine in the treatment of sexual dysfunction associated with selective serotonin reuptake inhibitors, J Clin Psychopharmacol, 15, 83, 10.1097/00004714-199502000-00014 Hollander, 1992, Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers, J Clin Psychiatry, 53, 207 Norden, 1994, Buspirone treatment of sexual dysfunction associated with selective serotonin re-uptake inhibitors, Depression, 2, 109, 10.1002/depr.3050020208 Bartlik, 1995, Psychostimulants apparently reverse sexual dysfunction secondary to selective serotonin re-uptake inhibitors, J Sex Marital Ther, 21, 264, 10.1080/00926239508414646 Lineberry, 1990, A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients, J Clin Psychiatry, 51, 194 Rothschild, 1995, Selective serotonin reuptake inhibitor—induced sexual dysfunction: Efficacy of a drug holiday, Am J Psychiatry, 152, 1514, 10.1176/ajp.152.10.1514 Tollefson, 1991, Antidepressant treatment and side effect consideration, J Clin Psychiatry, 52, 4 Kulig, 1986, Management of poisoning associated with “newer” antidepressant agents, Ann Emerg Med, 15, 1039/81, 10.1016/S0196-0644(86)80126-3 Montgomery, 1988, The benefits and risks of 5-HT uptake inhibitors in depression, Br J Psychiatry, 153, 7, 10.1192/S0007125000297237 Finley, 1994, Selective serotonin reuptake inhibitors: Pharmacologic profiles and potential therapeutic distinctions, Ann Pharmacother, 28, 1359, 10.1177/106002809402801207 DeVane, 1995, Comparative safety and tolerability of selective serotonin reuptake inhibitors, Hum Psychopharmacol, 10, S185, 10.1002/hup.470100907 Kasper, 1995, Do SSRIs differ in their antidepressant efficacy?, Hum Psychopharmacol, 10, S163, 10.1002/hup.470100905 Fisher, 1995, Postmarketing surveillance by patient self-monitoring: Preliminary data for sertraline versus fluoxetine, J Clin Psychiatry, 56, 288 Delini-Stula, 1995, Side-effects and drug-interaction profiles of moclobemide (RIMA) and fluoxetine, Pharmacopsychiatry, 28, 171 Montgomery, 1995, Safety of mirtazapine: A review, Int Clin Psychopharmacol, 10, 37, 10.1097/00004850-199512004-00006 1997, Serzone®, 776 Pai, 1996, Bruising associated with the use of fluoxetine, Ann Pharmacother, 30, 786, 10.1177/106002809603000716 Gunzberger, 1992, Adverse vascular effects associated with fluoxetine, Am J Psychiatry, 149, 1751, 10.1176/ajp.149.12.1751a Wilmshurst, 1996, Subhyaloid hemorrhage with fluoxetine, Eye, 10, 141, 10.1038/eye.1996.26 Yaryura-Tobias, 1991, Fluoxetine and bleeding in obsessive-compulsive disorder, Am J Psychiatry, 148, 949, 10.1176/ajp.148.7.949b Aranth, 1992, Bleeding, a side effect of fluoxetine, Am J Psychiatry, 149, 412, 10.1176/ajp.149.3.412a Humphries, 1990, Fluoxetine and the bleeding time, Arch Pathol Lab Med, 114, 727 Berk, 1995, Fluoxetine and hemostatic function: A pilot study, J Clin Psychiatry, 56, 14 Alderman, 1996, Effects of serotonin reuptake inhibitors on hemostasis, Ann Pharmacother, 30, 1232, 10.1177/106002809603001103 Woolfrey, 1993, Fluoxetine—warfarin interaction, BMJ, 307, 241, 10.1136/bmj.307.6898.241-b Dent, 1997, Warfarin—fluoxetine and diazepam—fluoxetine interaction, Pharmacotherapy, 17, 170, 10.1002/j.1875-9114.1997.tb03691.x Buckley, 1992, Drug interactions with warfarin, Med J Aust, 157, 479, 10.5694/j.1326-5377.1992.tb137313.x 1992, 520 Rowe, 1978, The effect of fluoxetine on warfarin metabolism in the rat and man, Life Sci, 23, 807, 10.1016/0024-3205(78)90515-5 Siegler, 1995, Risk factors for the development of hyponatremia in psychiatric inpatients, Arch Intern Med, 155, 953, 10.1001/archinte.155.9.953 Pillans, 1994, Fluoxetine and hyponatraemia—a potential hazard in the elderly, New Zealand Med J, 107, 85 Liu, 1996, Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: A review of spontaneous reports, Can Med Assoc J, 155, 519 Arya, 1994, Extrapyramidal symptoms with selective serotonin reuptake inhibitors, Br J Psychiatry, 165, 728, 10.1192/bjp.165.6.728 Leo, 1996, Movement disorders associated with the serotonin selective reuptake inhibitors, J Clin Psychiatry, 57, 449, 10.4088/JCP.v57n1002 Coulter, 1995, Fluoxetine and extrapyramidal side effects, Am J Psychiatry, 152, 122, 10.1176/ajp.152.1.122 Caley, 1992, Does fluoxetine exacerbate Parkinson's disease?, J Clin Psychiatry, 53, 278 Lipinski, 1989, Fluoxetine induced akathisia: Clinical and theoretical implications, J Clin Psychiatry, 50, 339 Lejoyeux, 1996, Antidepressant withdrawal syndrome. Recognition, prevention and management, Drug Ther, 5, 278 Price, 1996, A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal, Br J Clin Pharmacol, 42, 757, 10.1046/j.1365-2125.1996.00498.x Lazowick, 1995, Potential withdrawal syndrome associated with SSRI discontinuation, Ann Pharmacother, 29, 1284, 10.1177/106002809502901215 1993, Dystonia and withdrawal symptoms with paroxetine, Curr Probl Pharmacovigil, 19, 1 Barr, 1994, Physical symptoms associated with paroxetine discontinuation, Am J Psychiatry, 151, 289, 10.1176/ajp.151.2.289 Keuthen, 1994, Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine, J Clin Psychopharmacol, 14, 206, 10.1097/00004714-199406000-00010 Frost, 1995, Shock-like sensations after discontinuation of selective serotonin reuptake inhibitors, Am J Psychiatry, 152, 810, 10.1176/ajp.152.5.810a Hartmann, 1995, Physical symptoms associated with paroxetine withdrawal, Am J Psychiatry, 152, 1235, 10.1176/ajp.152.8.1235b Bloch, 1995, Severe psychiatric symptoms associated with paroxetine withdrawal, Lancet, 346, 57, 10.1016/S0140-6736(95)92691-7 Koopowitz, 1995, Paroxetine induced withdrawal effects, Hum Psychopharmacol, 10, 147, 10.1002/hup.470100210 Phillips, 1995, A possible paroxetine withdrawal syndrome, Am J Psychiatry, 152, 645, 10.1176/ajp.152.4.645b Pyke, 1995, Paroxetine withdrawal syndrome, Am J Psychiatry, 152, 149, 10.1176/ajp.152.1.149b Bhaumik, 1995, A naturalistic study in the use of anti-depressants in adults with learning disabilities and affective disorders, Hum Psychopharmacol, 10, 283, 10.1002/hup.470100405 Bhaumik, 1996, Treatment outcomes including withdrawal phenomena with fluoxetine and paroxetine in patients with learning disabilities suffering from affective disorders, Hum Psychopharmacol, 11, 337 Mallya, 1993, Is there a serotoninergic withdrawal syndrome?, Biol Psychiatry, 33, 851, 10.1016/0006-3223(93)90032-9 Otani, 1994, Mechanisms of the development of trazodone withdrawal symptoms, Int Clin Psychopharmacol, 9, 131, 10.1097/00004850-199400920-00011 Stoukides, 1991, Extrapyramidal symptoms upon discontinuation of fluoxetine, Am J Psychiatry, 148, 1263, 10.1176/ajp.148.9.1263a Kasantikul, 1995, Reversible delirium after discontinuation of fluoxetine, J Med Assoc Thailand, 78, 53 Einbinder, 1995, Fluoxetine withdrawal?, Am J Psychiatry, 152, 1235, 10.1176/ajp.152.8.1235a Cohen, 1997, Pharmacologic management of psychiatric illness during pregnancy and the postpartum period, Psychiatr Clin North Am, 4, 21 Altshuler, 1996, Pharmacologic management of psychiatric illness during pregnancy: Dilemmas and guidelines, Am J Psychiatry, 153, 592, 10.1176/ajp.153.5.592 Nulman, 1996, The safety of fluoxetine during pregnancy and lactation, Teratology, 53, 304, 10.1002/(SICI)1096-9926(199605)53:5<304::AID-TERA4>3.0.CO;2-0 Byrd, 1989, Developmental toxicology studies of fluoxetine hydrochloride (I) administered orally to rats and rabbits, Teratology, 39, 444 Stanford, 1995, In utero exposure to fluoxetine HCl increases hematoma frequency at birth, Pharmacol Biochem Behav, 45, 959, 10.1016/0091-3057(93)90147-L Horng, 1976, Effects of serotonin uptake inhibitor, Lilly 110140, on transport of serotonin in rat and human blood platelets, Biochem Pharmacol, 25, 865, 10.1016/0006-2952(76)90162-3 Hoyt, 1989, A reproduction study of fluoxetine hydrochloride (I) administered in the diet to rats, Teratology, 39, 459 Pastuszak, 1993, Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac) [see comments], JAMA, 269, 2246, 10.1001/jama.269.17.2246 Chambers, 1996, Birth outcomes in pregnant women taking fluoxetine [see comments], NEJM, 335, 1010, 10.1056/NEJM199610033351402 Nulman, 1997, Neurodevelopment of children exposed in utero to antidepressant drugs, NEJM, 336, 258, 10.1056/NEJM199701233360404 Marden, 1964, Congenital anomalies in the newborn infant, including minor variations: A study of 4,412 babies by surface examination for anomalies and buccal smear for sex chromatin, J Pediatr, 64, 357, 10.1016/S0022-3476(64)80188-8 Leppig, 1987, Predictive value of minor anomalies. I. Association with major malformations, J Pediatr, 110, 531, 10.1016/S0022-3476(87)80543-7 Goldstein, 1995, Effects of third trimester fluoxetine exposure on the newborn, J Clin Psychopharmacol, 15, 417, 10.1097/00004714-199512000-00005 Cohler, 1976, Pregnancy and birth complications among mentally ill and well mothers and their children, Soc Biol, 22, 269, 10.1080/19485565.1975.9988176 Briggs, 1994, 374 Kuller, 1996, Pharmacologic treatment of psychiatric disease in pregnancy and lactation: Fetal and neonatal effects, Obstet Gynecol, 87, 789, 10.1016/0029-7844(95)00476-9 Cooper, 1988, The safety of fluoxetine: An update, Br J Psychiatry, 155, 77, 10.1192/S000712500029733X Koren, 1996, First-trimester exposure to fluoxetine (Prozac). Does it affect pregnancy outcome?, Can Fam Phys, 42, 43 Shader, 1992, Does continuous use of fluoxetine during the first trimester of pregnancy present a high risk for malformation or abnormal development to the exposed fetus?, J Clin Psychopharmacol, 12, 441, 10.1097/00004714-199212000-00011 Taddio, 1996, Excretion of fluoxetine and its metabolite, norfluoxetine, in human breast milk, J Clin Pharmacol, 36, 42, 10.1002/j.1552-4604.1996.tb04150.x Duffull, 1996, Fluoxetine distribution in human milk, J Clin Pharmacol, 36, 1078, 10.1177/009127009603601112 Lester, 1993, Possible association between fluoxetine hydrochloride and colic in an infant, J Am Acad Child Adolesc Psychiatry, 32, 1253, 10.1097/00004583-199311000-00020 Burch, 1992, Fluoxetine/norfluoxetine concentrations in human milk, Pediatrics, 89, 676, 10.1542/peds.89.4.676 Isenberg, 1990, Excretion of fluoxetine in human breast milk, J Clin Psychiatry, 51, 169 Wisner, 1996, Antidepressant treatment during breastfeeding, Am J Psychiatry, 153, 1132, 10.1176/ajp.153.9.1132 Gjerdingen, 1994, The relationship of women's postpartum mental health to employment, childbirth, and social support, J Fam Pract, 38, 465 Green, 1993, Maternal depression: Bad for children's health, Contemp Pediatr, 10, 28 Neugebauer, 1997, Major depressive disorder in the 6 months after miscarriage, JAMA, 277, 383, 10.1001/jama.277.5.383 de Jonghe, 1992, The safety of antidepressants, Drugs, 43, 40, 10.2165/00003495-199200432-00007 Feierabend, 1995, Benign course in a child with a massive fluoxetine overdose, J Fam Pract, 41, 289 Wernicke, 1985, The side effect profile and safety of fluoxetine, J Clin Psychiatry, 46, 59 Rohrig, 1989, Fluoxetine overdose: A case report, J Anal Toxicol, 13, 305, 10.1093/jat/13.5.305 Kincaid, 1990, Report of a fluoxetine fatality, J Anal Toxicol, 14, 327, 10.1093/jat/14.5.327 1994, Prozac®, 880 Borys, 1992, Acute fluoxetine overdose: A report of 234 cases, Am J Emerg Med, 10, 115, 10.1016/0735-6757(92)90041-U Braitberg, 1995, Seizure after isolated fluoxetine overdose, Ann Emerg Med, 26, 234, 10.1016/S0196-0644(95)70157-5 Henry, 1995, Relative mortality from overdose of antidepressants, BMJ, 310, 221, 10.1136/bmj.310.6974.221 Tollefson, 1994, Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression, J Clin Psychopharmacol, 14, 163, 10.1097/00004714-199406000-00003 Guze, 1970, Suicide and primary affective disorders, Br J Psychiatry, 117, 437, 10.1192/bjp.117.539.437 Pallis, 1977, Seriousness of suicide attempt in relation to personality, Br J Psychiatry, 130, 253, 10.1192/bjp.130.3.253 Brent, 1988, The assessment and treatment of patients at risk for suicide, 7, 353 Murphy, 1994, Does fluoxetine induce suicidal thoughts?, Ir J Psychol Med, 11, 99, 10.1017/S079096670001243X Hagnell, 1981, Suicide rates in the Lundby study: Mental illness as a risk factor for suicide, Neuropsychobiology, 7, 248, 10.1159/000117857 Roose, 1988, Delusional depression, 76 1987, Serotonin, suicidal behaviour and impulsivity, Lancet, 2, 949 King, 1994, Serotonin and suicidality: The impact of acute fluoxetine administration. I: Serotonin and suicide, Isr J Psychiatry Relat Sci, 31, 271 Montgomery, 1992, Pharmacotherapy in the prevention of suicidal behavior, J Clin Psychopharmacol, 12, 27S, 10.1097/00004714-199204001-00006 Mann, 1991, The emergence of suicidal ideation and behavior during antidepressant pharmacotherapy, Arch Gen Psychiatry, 48, 1027, 10.1001/archpsyc.1991.01810350067011 Teicher, 1990, Emergence of intense suicidal preoccupation during fluoxetine treatment, Am J Psychiatry, 147, 207, 10.1176/ajp.147.2.207 King, 1991, Emergence of self destructive phenomena in children and adolescents during fluoxetine treatment, J Am Acad Child Adolesc Psychiatry, 30, 179, 10.1097/00004583-199103000-00003 King, 1991, Fluoxetine mechanism of action, J Am Acad Child Adolesc Psychiatry, 30, 849, 10.1097/00004583-199109000-00031 Power, 1992, Fluoxetine and suicidal behavior. Some clinical and theoretical aspects of a controversy, Br J Psychiatry, 161, 735, 10.1192/bjp.161.6.735 Beasley, 1992, Fluoxetine and suicide: A meta-analysis of controlled trials of treatment for depression, Int Clin Psychopharmacol, 6, 35, 10.1097/00004850-199206006-00006 Rothschild, 1991, Re-exposure to fluoxetine after serious suicide attempts by three patients: The role of akathisia, J Clin Psychiatry, 52, 491 Dasgupta, 1990, Additional cases of suicidal ideation associated with fluoxetine, Am J Psychiatry, 147, 1570, 10.1176/ajp.147.11.1570 Tollefson, 1993, Evaluation of suicidality during pharmacologic treatment of mood and non-mood disorders, Ann Clin Psychiatry, 5, 209, 10.3109/10401239309148820 Goldstein, 1993, Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction, J Clin Psychiatry, 54, 309 Warshaw, 1996, The relationship between fluoxetine use and suicidal behavior in 654 subjects with anxiety disorders, J Clin Psychiatry, 57, 158 Mann, 1993, Suicidal behavior and psychotropic medication. Consensus statement by the ACNP Council, March 2, 1992, Neuropsychopharmacology, 8, 177 Regier, 1990, Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) study, JAMA, 264, 2511, 10.1001/jama.264.19.2511 Lee, 1994, An open trial of fluoxetine in the treatment of premature ejaculation, Neuropsychopharmacology, 10, 160S Kara, 1996, The efficacy of fluoxetine in the treatment of premature ejaculation: A double-blind placebo controlled study, J Urol, 156, 1631, 10.1016/S0022-5347(01)65467-3 Fuller, 1996, The influence of fluoxetine on aggressive behavior, Neuropsychopharmacology, 14, 77, 10.1016/0893-133X(95)00110-Y Heiligenstein, 1992, Fluoxetine not associated with increased violence or aggression in controlled clinical trials, Ann Clin Psychiatry, 4, 383, 10.3109/10401239209150461 Fava, 1993, Anger attacks in unipolar depression, part 1: Clinical correlates and response to fluoxetine treatment, Am J Psychiatry, 150, 1158, 10.1176/ajp.150.8.1158 Salzman, 1995, Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder, J Clin Psychopharmacol, 15, 23, 10.1097/00004714-199502000-00005 Cornelius, 1993, Fluoxetine trial in suicidal depressed alcoholics, Psychopharmacol Bull, 29, 195 Roy, 1986, Alcoholism and suicide, Suicide Life-Threat Behav, 16, 244, 10.1111/j.1943-278X.1986.tb00354.x Angst, 1973, The course of monopolar depression and bipolar psychosis, Psychiatr Neurol Neurochir, 76, 489 Ballenger, 1979, Alcohol and central serotonin metabolism in man, Arch Gen Psychiatry, 36, 224, 10.1001/archpsyc.1979.01780020114013 Banki, 1981, Factors influencing monoamine metabolites and tryptophan in patients with alcohol dependence, J Neural Transm, 50, 89, 10.1007/BF01249132 Banki, 1984, Biochemical markers in suicidal patients, J Affect Disord, 6, 341, 10.1016/S0165-0327(84)80012-9 Murphy, 1982, Regional brain levels of monoamines in alcohol-preferring and nonpreferring lines of rats, Pharmacol Biochem Behav, 16, 145, 10.1016/0091-3057(82)90026-0 Mann, 1986, Increased serotonin2 and β-adrenergic receptor binding in the frontal cortices of suicide victims, Arch Gen Psychiatry, 43, 954, 10.1001/archpsyc.1986.01800100048007 Cornelius, 1995, Alcohol dependence. Preliminary report: Double-blind, placebo-controlled study of fluoxetine in depressed alcoholics, Psychopharmacol Bull, 31, 297 Janiri, 1996, Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics, Int Clin Psychopharmacol, 11, 109 Gerra, 1992, Effects of fluoxetine and Ca-acetyl-homotaurinate on alcohol intake in familial and nonfamilial alcoholic patients, Curr Ther Res, 52, 291, 10.1016/S0011-393X(05)80480-1 Shaw, 1989, Ethanol interactions with serotonin uptake selective and nonselective antidepressants: Fluoxetine and amitriptyline, Hum Psychopharmacol, 4, 113, 10.1002/hup.470040206 Hardens, 1995, Differential costs of treatment of depression with SSRIs, Hum Psychopharmacol, 10, S195, 10.1002/hup.470100908 Greenberg, 1993, The economic burden of depression in 1990, J Clin Psychiatry, 54, 405 Franco, 1995, The added costs of depression to medical care, PharmacoEconomics, 7, 284, 10.2165/00019053-199507040-00003 Katon, 1982, Depression and somatization: A review. Part I, Am J Med, 72, 127, 10.1016/0002-9343(82)90599-X Katon, 1982, Depression and somatization: A review. Part II, Am J Med, 72, 241, 10.1016/0002-9343(82)90816-6 Eisenberg, 1992, Treating depression and anxiety in primary care: Closing the gap between knowledge and practice, NEJM, 326, 1080, 10.1056/NEJM199204163261610 Von Korff, 1992, Disability and depression among high utilizers of health care. A longitudinal analysis, Arch Gen Psychiatry, 49, 91, 10.1001/archpsyc.1992.01820020011002 Wells, 1989, Detection of depressive disorder for patients receiving prepaid or fee-for-service care, JAMA, 262, 3298, 10.1001/jama.262.23.3298 Gerber, 1989, Recognition of depression by internists in primary care: A comparison of internist and “gold standard” psychiatric assessment, J Gen Intern Med, 4, 7, 10.1007/BF02596483 Shapiro, 1987, An experiment to change detection and management of mental morbidity in primary care, Med Care, 25, 327, 10.1097/00005650-198704000-00006 Block, 1988, Diagnosing depression among new patients in ambulatory training settings, J Am Board Fam Pract, 1, 91 Simon, 1995, Recognition, management, and outcomes of depression in primary care, Arch Fam Med, 4, 99, 10.1001/archfami.4.2.99 Covinsky, 1997, Relation between symptoms of depression and health status outcomes in acutely ill hospitalized older persons, Ann Intern Med, 126, 417, 10.7326/0003-4819-126-6-199703150-00001 Callahan, 1997, Association of symptoms of depression with diagnostic test charges among older adults, Ann Intern Med, 126, 426, 10.7326/0003-4819-126-6-199703150-00002 Judd, 1995, Economics of depression and cost-benefit comparisons of selective serotonin reuptake inhibitors and tricyclic antidepressants, Depression, 2, 173, 10.1002/depr.3050020309 DeVane, 1994, Pharmacokinetics of the newer antidepressants: Clinical relevance, Am J Med, 97, 13, 10.1016/0002-9343(94)90359-X Kilts, 1994, Recent pharmacologic advances in antidepressant therapy, Am J Med, 97, 3, 10.1016/0002-9343(94)90358-1 Lane, 1994, Reducing the economic burden of depression, Int Clin Psychopharmacol, 9, 229, 10.1097/00004850-199400940-00002 McCombs, 1990, The cost of antidepressant drug therapy failure: A study of antidepressant use patterns in a Medicaid population, J Clin Psychiatry, 51, 60 Sclar, 1994, Antidepressant pharmacotherapy: Economic outcomes in a health maintenance organization, Clin Ther, 16, 715 Thompson, 1996, Patterns of antidepressant use and their relation to costs of care, Am J Managed Care, 2, 1239 Sclar, 1995, Antidepressant pharmacotherapy: Economic evaluation of fluoxetine, paroxetine, and sertraline in a health maintenance organization, J Int Med Res, 23, 395, 10.1177/030006059502300601 Simpson, 1997, First-episode major depression: Few sex differences in course, Arch Gen Psychiatry, 54, 633, 10.1001/archpsyc.1997.01830190059006